Preparation method for obeticholic acid liposome tablets

A technology of obeticholic acid lipid and obeticholic acid lipid, which is applied in the field of preparation of obeticholic acid liposome tablets, and can solve the problem of increasing differences in drug efficacy, affecting product efficacy, and large fluctuation range of tablet content. question
CN110870852AInactive Publication Date: 2020-03-10HENAN TIANSHENG TAIFENG PHARM TECH CO LTD
2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HENAN TIANSHENG TAIFENG PHARM TECH CO LTD
Publication Date
2020-03-10
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The invention discloses a preparation method for obeticholic acid liposome tablets, which is characterized in that the obeticholic acid liposome is composed of obeticholic acid, lecithin and cholesterol, and then the obeticholic acid liposome and proper auxiliary materials are prepared into the obeticholic acid liposome tablet. The obeticholic acid liposome contains the following components: 1 part of obeticholic acid, 5-10 parts of lecithin and 1-5 parts of cholesterol. The obeticholic acid liposome tablet comprises the following components in parts by weight: 1 part of obeticholic acid liposome, 1-5 parts of filler, 0-0.5 part of disintegrating agent, 0-0.5 part of adhesive and 0-0.2 part of lubricant. According to the technical scheme, by utilizing the advantages of the liposome, the drug absorption and utilization of obeticholic acid are improved, and the dosage can be effectively reduced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of pharmaceutical preparations. Specifically, the invention relates to a preparation method of obeticholic acid liposome tablets. Background technique

[0002] Obeticholic acid is a farnesoid X receptor agonist, which indirectly inhibits the gene expression of cytochrome 7A1 (CYP7A1) by activating farnesoid X receptor. Since CYP7A1 is the rate-limiting enzyme of bile acid biosynthesis, obeticholic acid can inhibit bile acid synthesis for the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease. Obeticholic acid was successfully developed by Intercept Pharmaceuticals, Inc. in the United States. In May 2014, the US FDA granted Intercept Pharmaceuticals a fast track approval for obeticholic acid. Obeticholic acid is the first drug developed for the treatment of cholestatic liver disease in 20 years, and it is also the second drug approved by the FDA for the treatment of primary biliary c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More